Enliven Therapeutics financials
$46.51+1.09%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$37.2M | -$27.8M | -$34.3M | -$25.1M | -$28.6M | -$31.7M | -$26.9M | -$27.1M | -$24.6M | -$26.0M | -$22.7M | -$24.2M |
| Net income | -$32.5M | -$23.6M | -$29.7M | -$20.1M | -$25.3M | -$28.5M | -$23.2M | -$23.2M | -$19.9M | -$22.7M | -$19.4M | -$20.8M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.49 | $-0.38 | $-0.48 | $-0.32 | $-0.49 | $-0.57 | $-0.46 | $-0.48 | $-0.41 | $-0.54 | $-0.46 | $-0.51 |
| EBITDA | -$37.2M | -$27.8M | -$34.2M | -$25.0M | -$28.5M | -$31.6M | -$26.8M | -$27.0M | -$24.5M | -$25.9M | -$22.7M | -$24.2M |
| Operating cash flow | -$18.5M | -$19.3M | -$15.8M | -$13.3M | -$17.1M | -$24.1M | -$17.2M | -$12.2M | -$20.4M | -$23.4M | -$12.5M | -$15.9M |
| Free cash flow | -$18.6M | -$19.3M | -$15.8M | -$13.3M | -$17.2M | -$24.1M | -$17.2M | -$12.2M | -$20.4M | -$23.4M | -$12.5M | -$15.9M |
| Diluted shares | 66.2M | 62.8M | 62.4M | 62.1M | 52.1M | 50.1M | 49.9M | 48.3M | 48.1M | 42.0M | 41.7M | 41.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $135.5M | $132.2M | $98.9M | $101.7M | $119.4M | $101.7M |
| Short-term investments | $759.6M | $320.2M | $363.7M | $375.8M | $371.1M | $187.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $910.2M | $464.9M | $476.2M | $490.9M | $503.9M | $302.6M |
| Total liabilities | $15.1M | $11.5M | $16.6M | $14.8M | $15.4M | $14.3M |
| Shareholders' equity | $895.1M | $453.4M | $459.6M | $476.1M | $488.5M | $288.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology